XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenues (Tables) | 9 Months Ended
--- | ---
Oct. 01, 2021
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | Revenues consisted of the following (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |
Product revenues: |  |  |  |  |  |  |  |  |
Gross product revenues | $ | 357,462 |  |  | $ | 220,401 |  |  | $ | 1,051,871 |  |  | $ | 702,865 |  |  |
Discounts and allowances | (94,345) |  |  | (51,814) |  |  | (277,294) |  |  | (161,668) |  |  |
Net product revenues | 263,117 |  |  | 168,587 |  |  | 774,577 |  |  | 541,197 |  |  |
Collaboration revenues: |  |  |  |  |  |  |  |  |
License revenues | 49,694 |  |  | 33,205 |  |  | 116,862 |  |  | 113,318 |  |  |
Collaboration services revenues | 15,612 |  |  | 29,300 |  |  | 92,391 |  |  | 62,971 |  |  |
Total collaboration revenues | 65,306 |  |  | 62,505 |  |  | 209,253 |  |  | 176,289 |  |  |
Total revenues | $ | 328,423 |  |  | $ | 231,092 |  |  | $ | 983,830 |  |  | $ | 717,486 |  |  |
Net product revenues by product were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |
CABOMETYX | $ | 259,791 |  |  | $ | 159,555 |  |  | $ | 759,000 |  |  | $ | 522,381 |  |  |
COMETRIQ | 3,326 |  |  | 9,032 |  |  | 15,577 |  |  | 18,816 |  |  |
Net product revenues | $ | 263,117 |  |  | $ | 168,587 |  |  | $ | 774,577 |  |  | $ | 541,197 |  |  |
Schedule of Concentration Risks | The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |
Ipsen Pharma SAS | 12 | % |  | 16 | % |  | 17 | % |  | 16 | % |  |
Affiliates of McKesson Corporation | 15 | % |  | 12 | % |  | 15 | % |  | 13 | % |  |
Affiliates of CVS Health Corporation | 16 | % |  | 14 | % |  | 15 | % |  | 15 | % |  |
Affiliates of AmerisourceBergen Corporation | 16 | % |  | 11 | % |  | 14 | % |  | 11 | % |  |
Affiliates of Optum Specialty Pharmacy | 9 | % |  | 10 | % |  | 9 | % |  | 11 | % |  |
Takeda Pharmaceutical Company Limited | 7 | % |  | 10 | % |  | 3 | % |  | 7 | % |  |
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
| September 30, 2021 |  | December 31, 2020 |  |  |  |
Ipsen Pharma SAS | 24 | % |  | 23 | % |  |  |  |
Affiliates of McKesson Corporation | 19 | % |  | 12 | % |  |  |  |
Affiliates of AmerisourceBergen Corporation | 16 | % |  | 11 | % |  |  |  |
Affiliates of CVS Health Corporation | 13 | % |  | 11 | % |  |  |  |
Takeda Pharmaceutical Company Limited | 3 | % |  | 10 | % |  |  |  |
Schedule of Revenues Disaggregated by Geographic Region | Revenues by geographic region were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |
U.S. | $ | 266,436 |  |  | $ | 171,552 |  |  | $ | 783,583 |  |  | $ | 549,379 |  |  |
Europe | 38,095 |  |  | 36,006 |  |  | 162,822 |  |  | 117,959 |  |  |
Japan | 23,892 |  |  | 23,534 |  |  | 37,425 |  |  | 50,148 |  |  |
Total revenues | $ | 328,423 |  |  | $ | 231,092 |  |  | $ | 983,830 |  |  | $ | 717,486 |  |  |
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances | The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
| Chargebacks, Discounts for Prompt Payment and Other |  | Other Customer Credits/Fees and Co-pay Assistance |  | Rebates |  |  |  | Total
Balance at December 31, 2020 | $ | 9,853 |  |  | $ | 3,279 |  |  | $ | 17,404 |  |  |  |  | $ | 30,536 |
Provision related to sales made in: |  |  |  |  |  |  |  |  |
Current period | 178,083 |  |  | 22,945 |  |  | 74,851 |  |  |  |  | 275,879 |
Prior periods | (22) |  |  | (225) |  |  | 1,662 |  |  |  |  | 1,415 |
Payments and customer credits issued | (171,416) |  |  | (18,789) |  |  | (70,007) |  |  |  |  | (260,212) |
Balance at September 30, 2021 | $ | 16,498 |  |  | $ | 7,210 |  |  | $ | 23,910 |  |  |  |  | $ | 47,618 |
Schedule of Other Assets and Other Liabilities | Contract liabilities were as follows (in thousands):
| September 30, 2021 |  | December 31, 2020
Contract liabilities: |  |  |
Current portion (1) | $ | 7,535 |  |  | $ | 1,790 |
Long-term portion (1) | 9,444 |  |  | 3,755 |
Total contract liabilities | $ | 16,979 |  |  | $ | 5,545 |
____________________ (1) Presented in Other current liabilities and Long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.

X
- Definition Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] + References No definition available. + Details
Name: | exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix: | exel_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration